Savara Inc. (NASDAQ:SVRA) Receives $9.00 Average PT from Brokerages

Shares of Savara Inc. (NASDAQ:SVRA) have received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $9.00.

Several equities research analysts have recently weighed in on SVRA shares. HC Wainwright reissued a “buy” rating on shares of Savara in a research note on Monday, March 16th. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. William Blair set a $10.00 price objective on Savara in a research note on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Tuesday.

Savara Stock Performance

SVRA opened at $4.94 on Tuesday. The firm has a market cap of $1.01 billion, a PE ratio of -9.32 and a beta of 0.32. The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $5.51 and a 200-day simple moving average of $5.33. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $7.01.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities analysts predict that Savara will post -0.48 EPS for the current fiscal year.

Institutional Trading of Savara

Several hedge funds and other institutional investors have recently modified their holdings of SVRA. Prudential Financial Inc. acquired a new stake in shares of Savara in the second quarter worth $30,000. BNP Paribas Financial Markets boosted its position in shares of Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares during the period. Brevan Howard Capital Management LP acquired a new stake in shares of Savara in the second quarter worth $33,000. Russell Investments Group Ltd. boosted its position in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Savara in the third quarter worth $44,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.